Netrin-1 & Hepatocellular Carcinoma HCC

• Conditions: HCC
• Interventions: Procedure: Quantification of netrin-1 signals by antibody-based approaches

• Registration Number: NCT04766736
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-01
• Status Verified: 2021-02
• Study First Submitted: 2021-02-19
• Study First Submitted QC: 2021-02-19
• Last Update Submitted: 2021-02-19
• Study First Posted: 2021-02-23
• Last Update Posted: 2021-02-23
• Primary Completion: 2021-06-30
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

• any patient suffering from HCC
• age >18
• informed consent provided

Read More

Exclusion Criteria

• absence of informed consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)	Quantification of netrin-1 signals by antibody-based approaches	The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)	Quantification of netrin-1 signals by antibody-based approaches	The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)

Primary Outcome Measures

Name	Time	Method
Netrin-1 expression patterns in HCC samples	Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.	Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used.

Trial Locations

Locations (1)

Hepatogastroenterology service of the Croix-Rousse Hospital; 🇫🇷 Lyon, France